Roles of PKA, PI3K, and cPLA2 in the NO-mediated negative inotropic effect of β2-adrenoceptor agonists in guinea pig right papillary muscles

American Journal of Physiology - Cell Physiology

Volumn 294, Issue 1, 2008, Pages

  Faucher, Fabien A ^a   Gannier, François E ^a   Lignon, Jacques M ^a   Cosnay, Pierre ^a   Malécot, Claire O ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

Author keywords

adrenoceptor antagonists; Active conformations; Cardiac contractility; G s Gi coupling; Salbutamol

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ACETYLCHOLINE; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL L TYPE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; INDOMETACIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OKADAIC ACID; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; SALBUTAMOL; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EQUILIBRIUM CONSTANT; GUINEA PIG; HEART PAPILLARY MUSCLE; HEART VENTRICLE WALL; INOTROPISM; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALBUTEROL; ANIMALS; ARACHIDONIC ACID; ATENOLOL; CATECHOLAMINES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; GROUP IV PHOSPHOLIPASES A2; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GUINEA PIGS; MALE; MYOCARDIAL CONTRACTION; NITRIC OXIDE; PAPILLARY MUSCLES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROPANOLAMINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

ANIMALIA; CAVIA;

EID: 38349114026     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00231.2007     Document Type: Article

References (58)

1. 2-adrenergic cardiac effects in rat. J Biol Chem 280: 18881-18890, 2005.
2. Ariens EJ, Van Rossum JM. pDx, pAx and pDx values in the analysis of pharmacodynamics. Arch Int Pharmacodyn 110: 275-299, 1957.
3. 2-adrenergic regulation. Proc Natl Acad Sci USA 103: 7500-7505, 2006.
4. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 17: 1846-1858, 1997.
5. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 90: 347-351, 1993.
6. 2- adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203-242, 1991.
7. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51: 651-689, 1999.
8. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 100: 323-337, 2006.
9. Buchheit KH, Hoffmann A, Pfannkuche HJ. In vitro and in vivo effects of SCA40 on guinea pig airways. Naunyn Schmiedebergs Arch Pharmacol 355: 217-223, 1997.
10. Casadei B, Sears CE. Nitric-oxide-mediated regulation of cardiac contractility and stretch responses. Prog Biophys Mol Biol 82: 67-80, 2003.
11. 2+ channels. Biophys J 79: 2547-2556, 2000.
12. 2-adrenergic receptor to different G proteins by protein kinase A. Nature 390: 88-91, 1997.
13. v1.2. Science 293: 98-101, 2001.
14. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2006.
15. 2+ current in cat atrial myocytes. J Physiol 542: 711-723, 2002.
16. 2- adrenoceptors in single myocytes from human ventricle. Circulation 88: 854-863, 1993.
17. i3 proteins by basic secretagogues induces exocytosis through phospholipase Cβ and arachidonate release through phospholipase Cγ in mast cells. J Immunol 167: 4805-4813, 2001.
18. Fischmeister R, Castro LRV, Abi-Gerges A, Rochais F, Jurevic̀ius J, Leroy J, Vandecasteele G. Compartmentation of cyclic nucleotide signaling in the heart. The role of cyclic nucleotide phosphodiesterases. Circ Res 99: 816-828, 2006.
19. 3- Adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21: 426-431, 2000.
20. Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273: 17979-17982, 1998.
21. + exchange. Nature 392: 626-630, 1998.
22. i-protein switching. Br J Pharmacol 138: 1188-1189, 2003.
23. 2+ channels in guinea pig ventricular myocytes. Am J Physiol Heart Circ Physiol 273: H1669-H1676, 1997.
24. 2- adrenoceptors. Br J Pharmacol 131: 124-130, 2000.
25. Hopwood AM, Harding SE, Harris P. Pertussis toxin reduces the antiadrenergic effect of 2-chloroadenosine on papillary muscle and the direct negative inotropic effect of 2-chloroadenosine on atrium. Eur J Pharmacol 141: 423-428, 1987.
26. 2-adrenergic stimulation. Circ Res 91: 46-53, 2002.
27. Kanai AJ, Mesaros S, Finkel MS, Oddis CV, Birder LA, Malinski T. β-Adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol Cell Physiol 273: C1371-C1377, 1997.
28. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232-238, 1995.
29. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611, 2001.
30. 2-adrenoceptor. Eur J Pharmacol 348: 123-133, 1998.
31. 3H-ICI 118,551 and blocking potency of ICI 118,551. Naunyn Schmiedebergs Arch Pharmacol 331: 40-51, 1985.
32. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 24: 261-274, 2006.
33. 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 117: 435-442, 1996.
34. Massion PB, Pelat M, Belge C, Balligand JL. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A 142: 144-150, 2005.
35. Maslowska M, Legakis H, Assadi F, Cianflone K. Targeting the signaling pathway of acylation stimulating protein. J Lipid Res 47: 643-652, 2006.
36. 2- adrenergic receptor. FEBS Lett 399: 188-191, 1996.
37. Molenaar P, Summers RJ. Characterization of beta-1 and beta-2 adrenoceptors in guinea pig atrium: functional and receptor binding studies. J Pharmacol Exp Ther 241: 1041-1047, 1987.
38. 2-adrenoceptors in guinea-pig atrioventricular conducting system. J Mol Cell Cardiol 22: 483-495, 1990.
39. Motulsky FJ, Christopoulos A. Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting [Online]. San Diego, CA: GraphPad Software, 2003 (http://www.graphpad.com).
40. 2-adrenoceptors mediating positive inotropic effects in guinea-pig right ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 16: 529-533, 1997.
41. Ostrom RS, Insel PA. The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 143: 235-245, 2004.
42. 1-adrenergic/cAMP pathway. J Biol Chem 274: 628-637, 1999.
43. 2-Adrenergic signaling in human heart: shift from the cyclic AMP to the arachidonic acid pathway. Mol Pharmacol 64: 1117-1125, 2003.
44. 2-adrenergic receptor agonists: novel regulatory mechanism of keratinocyte migration. J Biol Chem 278: 22555-22562, 2003.
45. Saucerman JJ, McCulloch AD. Cardiac β-adrenergic signaling from subcellular microdomains to heart failure. Ann NY Acad Sci 1080: 348-361, 2006.
46. Sengupta S, Xiao YJ, Xu Y. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J 17: 1570-1572, 2003.
47. 2 adrenergic receptor. J Biol Chem 281: 1261-1273, 2006.
48. 2-adrenergic receptors with protein kinases and phosphatases and the role of gravin. J Biol Chem 274: 1588-1595, 1999.
49. Silfani TN, Freeman EJ. Phosphatidylinositide 3-kinase regulates angiotensin II-induced cytosolic phospholipase A2 activity and growth in vascular smooth muscle cells. Arch Biochem Biophys 402: 84-93, 2002.
50. Steinberg SF. The molecular basis for distinct β-adrenergic receptor subtype actions in cardiomyocytes. Circ Res 85: 1101-1111, 1999.
51. Sun Y, Huang J, Xiang Y, Bastepe M, Jüppner H, Kobilka BK, Zhang JJ, Huang XY. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 26: 53- 64, 2007.
52. Voss HP, Shukrula S, Wu TS, Donnell D, Bast A. A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther 271: 386-389, 1994.
53. Westfall DP, Fleming WW. Sensitivity changes in the dog heart to norepinephrine, calcium and aminophylline resulting from pretreatment with reserpine. J Pharmacol Exp Ther 159: 98-106, 1968.
54. Wilson C, Lincoln C. β-Adrenoceptor subtypes in human, rat, guinea pig, and rabbit atria. J Cardiovasc Pharmacol 6: 1216-1221, 1984.
55. 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47: 322-329, 1995.
56. i proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84: 43-52, 1999.
57. Yamamoto Y, Koike K. The effects of beta-adrenoceptor agonists on KCl-induced rhythmic contraction in the ureter of guinea pig. J Smooth Muscle Res 36: 13-19, 2000.
58. Zheng M, Zhu W, Han Q, Xiao RP. Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling. Pharmacol Ther 108: 257-268, 2005.